Journal of Cellular Immunology
ISSN: 2689-2812

Review Article - Journal of Cellular Immunology (2020) Volume 2, Issue 2

Multiple Roles of the Interleukin IL-17 Members in Breast Cancer and Beyond

Stephane Potteaux1,2*, Jacqueline Lehmann-Che1, Armand Bensussan1, Richard Le Naour2,Yacine Merrouche2,3

1Unité Inserm U976 (Immunologie humaine, Pathopysiologie, Immunothérapie); Hôpital Saint-Louis, 1 rue Claude Vellefaux, 75010 Paris, France

2IRMAIC, EA7509, Université Reims-Champagne-Ardenne, 51 rue Cognacq-Jay, 51095 Reims CEDEX, France

3Institut Godinot, 1 rue du Général Koenig, 51100 Reims, France

*Corresponding Author:
Stephane Potteaux

Received date: January 22, 2020; Accepted date: February 21, 2020

Citation: Potteaux S, Lehmann-Che J, Bensussan A, Le Naour R, Merrouche Y. Multiple Roles of the Interleukin IL-17 Members in Breast Cancer and Beyond. J Cell Immunol. 2020; 2(2): 55-64.

Copyright: © 2020 Potteaux S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Interleukin-17 (IL-17) family proteins are involved in the control of infections. When unrestrained, these cytokines contribute to the development of chronic inflammatory diseases. The IL-17 family contains 6 members: IL-17A to F. In this review, we outline the current knowledge on the roles of each IL-17 member on breast cancer.


IL-17, Breast tumor, Microenvironment, Cytokines, Stroma, Immune cells, Inflammation

Breast Cancer Generalities

Worldwide, breast cancer is the most-common invasive cancer in women. Commonly used treatments include surgery, hormonal therapy, radiotherapy, chemotherapy and targeted therapy. Failure of these treatments is often due to intrinsic or acquired resistances and is responsible for most relapses of cancer [1]. Heterogeneity among patients and tumors, together with the versatility of cancer make drug resistance more challenging to deal with. Drug combination is often proposed to overcome treatment resistance and novel targets are to be found to achieve better outcomes. According to the expression of molecular markers (estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)), breast cancer can be divided into several subtypes: luminal A, luminal B, HER2-amplified, and triple-negative. The latter is defined by the lack of ER and PR expression, as well as the absence of HER2 amplification, which makes it unresponsive to hormonal therapy or HER2-targeted agents. Nevertheless, recent data highlighted the efficacy of therapeutic antibodies directed against immune checkpoint PD-1/PDL-1 in some breast cancer subtypes [2]. As immunotherapy enters clinical practice, it is important to identify new predictive biomarkers and potential targets.

Malignant Tumors are Wounds That Do Not Heal

Mediators that allow communication between tumor cells and cells of their microenvironment are potential targets for immunotherapy. Among them, cytokines control and shape the tumor microenvironment, in part through modulation of angiogenesis, cell migration and phenotype. In the tumor microenvironment, immune cells transitory fight both against and for tumor cell expansion, depending on tumor phases. Indeed, as proposed by Dunn et al. [3], during the elimination phase, immune surveillance successfully eradicates malignant cells; at equilibrium, the immune system exerts control over tumor cells; during the escape phase, tumor cells evade immune mechanisms and expand. Transition from one to the other phase may result from dysbalanced expression of mediators of inflammation and resolution of inflammation in response to environmental factors, to the tumor itself or even by anti-tumor therapies [4]. At the cellular level, inflammation and resolution of inflammation are finely driven by leukocyte migration, apoptosis and efferocytosis. Results linking efferocytosis to cancer progression are increasing. The milk fat globule-epidermal growth factor (EGF) factor 8 protein (MFG-E8), a key molecule of efferocytosis, is present at high levels in triple-negative breast cancers and its invalidation sensitizes triple-negative breast cancers to cisplatin treatment [5]. However, opposite results were found in ER(+) and HER2-amplified breast cancers [5]. Targeting of phosphatidyl serine, which is expressed at the cell membrane during cell apoptosis or in response to docetaxel, showed efficacy in breast cancer therapy [6,7]. New approaches in anticancer therapy propose to simultaneously block the proinflammatory response and activate endogenous resolution programs. For instance, preoperative stimulation of resolution and inflammation blockade with nonsteroidal anti-inflammatory drugs or resolvins, eradicated micrometastasis formation during tumor resection [8].

At the molecular level, chemokines, such as CCL2 and CCL5, and cytokines from the tumor microenvironment play crucial roles in leukocyte migration, phenotype and immune responses. Type 1 inflammation, characterized by production of interleukin-1β (IL-1β), IL-6, tumor necrosis factor–α (TNF-α), and interferon-γ (IFN-γ), is proinflammatory and antifibrogenic. Type 2 inflammation, characterized by production of IL-4, IL-5, IL-10, IL- 13, IL-25, and IL-33, is associated with reduced tissue inflammation but positively correlates with tissue fibrosis. Imbalance between type 1 and type 2 inflammation is the major driver of fibrosis. Type 3 inflammation is characterized by production of IL-17A, IL-17F, IL-22, and IL-26 produced by neutrophils, mast cells, group 3 innate lymphoid cells (ILC3), T helper 17 (Th17) and Th22 cells. Type 3 cytokines play an important physiological role in tissue homeostasis but can be pathogenic. Deregulation of type 3 immunity is associated with abnormal tissue repair, chronic inflammatory diseases, and some cancers. The cytokine equilibrium in the tumor microenvironment may then contribute to the dogma proposing that malignant tumors are described as wounds that do not heal or alternatively as wounds that overheal [9].

Understanding of the biological milieu associated with breast cancer has important implications for biobehavioral research. Circulating cytokines may image the temporal stage of cancer and can serve as biomarkers for prognosis and/or target for immunotherapy. Several years ago, proteomic analysis had showed that three cytokines, granulocyte colony-stimulating factor (G-CSF), IL-6, and IL-17, were markedly increased in women with breast cancer as compared with those in women who did not have breast cancer [10]. Very recently, a study showed that serum IL-17 was up-regulated in breast cancer patients and that high levels of IL-17 also correlated with poor clinical outcomes [11]. The association of serum IL- 17 levels with an increased level of both basic fibroblast growth factor (bFGF) and G-CSF was correlated with poor disease-free survival among breast cancer patients. The study suggested that systemic IL-17 levels correlated with pathological complete response rates in breast cancer patients [11]. IL-17-blocking monoclonal antibodies may then be interesting to use in breast cancer. Nevertheless, controversial experimental studies have pointed out both pro and anti-tumoral roles for IL-17. In this review, we will present the implication of IL-17 family members in the hallmarks of oncogenesis and in breast cancer development.

The IL-17 Family Members

Originally thought to be produced by Th17 lymphocytes, IL-17 is now found to be secreted by many innate-like lymphocytes including, γδ T cells, invariant natural killer cells (iNKT), and ILC3, but also stromal cells, tumor cells and some myeloid cells. Many of these cell types are present in relatively high numbers at mucosal surfaces making IL-17 members important mediators of both host defense and homeostatic physiological processes at mucosal barrier sites. The wide cellular distribution of IL-17R contributes to the pleiotropic nature of the IL-17 family, allowing it to partake in a variety of physiological processes both beneficial and detrimental.

The IL-17 cytokine family of cytokines consists of 6 proteins (IL-17A to IL-17F) and 5 receptors (IL-17RA to IL-17RE). IL-17A, the founding and most studied member of the IL-17 family, was cloned in 1993 and initially named CTLA-8 [12]. IL-17F shares the highest degree of conservation to IL-17A (55%) and is commonly produced by the same cell types. IL-17E, also known as IL-25, displays the lowest degree of sequence conservation (16%). IL-17A, IL-17F, IL-17C and IL-17E function in host defense against pathogens and play various but not fully understood roles in mediating inflammation in autoimmune, allergic and chronic inflammatory conditions. Given the central role of IL-17A in autoimmunity, much effort has focused on the development of neutralizing antibodies for therapeutic use. IL-17A-blocking monoclonal antibodies secukinumab and ixekizumab recently received FDA-approval for the treatment of psoriasis, ankylosing spondylitis and psoriatic arthritis. Besides, it was also found that IL-17 cytokines bind IL-17 receptors on tumor cells, signaling the downstream activation of transcription factors (nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), signal transducer and activator of transcription (STAT), and activator protein 1 (AP-1)), kinases (mitogenactivated protein kinase (MAPK) and human epidermal growth factor receptor 1 (HER1)), tissue remodeling matrix metalloproteinases (MMPs), and anti-apoptotic proteins (Akt, Erk, mTOR, Bcl-2, and Bax) in a myriad of cancers [13,14].

IL-17A and IL-17F

Closely related molecules IL-17F and IL-17A are secreted as both homodimeric and heterodimeric forms, all of which are biologically active. The IL-17F homodimer is 100-fold less active than the IL-17A homodimer, but its expression was shown to be 10-fold higher than the IL-17A homodimer form, in the conditioned medium of human activated CD4+ T cells [15]. IL-17A is mostly secreted as a heterodimeric form with IL-17F, suggesting that the activity of IL-17A is, at least, partially attributed to the IL-17F/IL-17A heterodimeric cytokine. IL-17A and F were initially identified in T cells also expressing IL-21, IL-22 and granulocyte-macrophage colony stimulating factor (GM-CSF), which led to the denomination of a unique Th cell subset identified as Th17 [16]. The transition of naïve T cells to Th17 cells was due to a combination of IL-1β, IL-6, TGF-β and IL-21 for initial commitment, and IL-23 for full acquisition of their pathogenic capacity [17]. Later studies showed that IL-17A and F are also produced by CD8+ T cells, innate tissue-resident, Th17 and NKT cells. These cells share a common dependence on IL-23 and on the transcription factor ROR-γt for IL-17 production, and express the chemokine receptor CCR6, which binds C-C motif chemokine ligand 20 (CCL20) [18,19]. Recent reports have shown the expression of IL-17A by myeloid cells, including macrophages, neutrophils and mast cells, with possible artifacts due to their propensity for phagocytosis of Il-17A producing cells. IL-17A, IL- 17F and IL-17A/F signaling requires the formation of a heterotrimeric receptor complex comprising two IL-17RA and one IL-17RC [20]. The strength of IL-17 signaling varies widely among different cell types, in part due to differential expression profiles of IL-17RA and RC and binding affinities of IL-17A and IL-17F for these receptors [21,22]. Indeed, IL-17RA is highly expressed by leukocytes, whereas IL-17RC is preferentially, but not exclusively expressed in nonimmune cells [23]. Cells that express low levels or lack IL-17RC do not respond to IL-17A and F. Nevertheless, chronic inflammation can enhance the expression of IL-17RA and RC in some circulating leukocyte subsets, suggesting that the IL-17A/F signaling may be amplified in certain conditions. This is the case in bullous pemphigoid [24]. IL-17A and F signal leads to Act1-TRAF6-mediated activation of transcription factors NF-κB, MAPK-AP-1, and C/EBP. Downstream of IL- 17R, TRAF3 also associates with Act1 to inhibit TRAF6 signaling (reviewed in [25]).

IL-17A and F induce a proinflammatory milieu with enhanced cytokine, chemokine, growth factor and MMP production. The biological effects of IL-17A and F include thrombosis, inflammation and bone degradation. IL- 17A indirectly induces neutrophil expansion, migration and survival through synthesis of G-CSF, GM-CSF and IL-8 [26]. IL-17-A also stimulates the apoptosis and efferocytosis of neutrophils by macrophages in response to IL-10 and glucocorticoids [27,28]. These results contrast with the study by Hou et al, who showed that during the acute phase of inflammation, in experimental autoimmune myocarditis, IL-17A attenuates efferocytosis by monocytes [29]. IL-17A increases fibrosis through increased TGF-β expression and signaling pathways. Indeed, IL-17A enhanced responses to TGF-β by increasing cell surface expression of its receptor on stellate cells and allowing the activation of SMAD2/3 transcription factors in response to suboptimal doses of TGF-β [30]. IL-17A also dramatically increases the release of angiogenic factors, such as IL-8 [31] and vascular endothelial growth factor (VEGF) [32]. IL-17A, therefore potentiates both induction and resolution of inflammation, which might explain the controversy around its implication in several inflammatory diseases [33].

In breast cancers, studies have shown higher expression of IL-17A on tumor infiltrating lymphocytes and macrophages when compared to normal breast tissue [34,35]. Positive correlations were found between the number of IL-17-expressing cells and the histological grade of the tumors, aggressiveness of cancers and shorter disease-free survival [36-38]. Polymorphisms in the IL- 17A gene are associated with increased breast cancer risk in a Chinese patient population [39]. All together, these studies suggest that IL-17A exerts pro-tumoral activities in breast cancer. On the other hand, several papers suggest a possible anti-tumoral effect of IL-17A. Horlock et al. found that patients with HER2-positive breast carcinomas have reduced numbers of circulating Th17 cells and that treatment with anti-HER2 trastuzumab increased Th17 frequencies [40]. Yang et al. found that Th17 cells and expression of IL-17, IL-1β, and IL-6 cytokines were higher in breast cancer tissue compared to normal breast tissue but found a negative correlation between the numbers of Th17 cells and the stage of cancer [34]. Although these studies are mostly based on correlations and associations, they challenge the pro-tumoral effect of IL-17A.

Experimental models of breast cancers mainly support the pro-tumoral role of IL-17A. IL-17R knockdown or TGF-β neutralization, upstream of IL-17 synthesis, decreased tumor growth in vivo in 4T1 mouse mammary carcinoma model [41]. Also, IL-17A neutralization inhibited tumor growth and prevented the migration of tumorigenic neutrophils in various murine mammary tumor models [42,43]. In the study of Novitskiy et al., results supported that in human breast cancer, as well as in mouse models, decreased TGF-β signaling is correlated with increased CXCL1/5 genes and Th17 response [43].

Mechanistically, IL-17A both plays on tumor cells and cells in microenvironment (Figures 1 and 2). IL-17A was shown to promote metalloproteinase (MMP)-dependent invasion of breast cancer cell lines MDA-435 and MDAMB231 [44], to inhibit cell death in 4T1, MDA-MB-231 and EM6 BC cell lines in a TGF-β dependent manner [41], to stimulate cell proliferation in MCF-7, through tyrosine kinase activation [45] and in MDA-MB231 through signal transducer and activator of transcription 3 (STAT3) activation [46]. IL-17A was also shown to stimulate the release of IL6 and C-C motif chemokine ligand 20 (CCL20) by 4T-1 tumor cells [42]. Interestingly, IL-17A was found to promote resistance to docetaxel-based chemotherapy in various cell lines, through activation of the extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) pathway [35]. In the tumor microenvironment, IL-17A recruits and drives myeloid cells toward suppressive and angiogenic [47] phenotype, through G-CSF and proinflammatory cytokines (such as IL-6 and TNF-α) release, which is reversed by antagonism of IL-17A [48-50]. On the other hand, IL-17A was also found to inhibit myeloid-derived suppressor cell (MDSC) proliferation and to trigger their apoptosis, which suggests that other cytokines take over IL-17A to maintain MDSCs in the tumor microenvironment [51].

The role of IL-17F in breast tumor development has not been well described. Considering the high homology of IL-17F to –A, it is expected that many of the biological effects of IL-17F are similar to those of IL-17A, although differential function of IL-17F versus A was recently suggested [52].


IL-17B is expressed in many cell types including tumor cells and neutrophils [53], but not T cells [54]. IL-17B binds to IL-17RA/IL-17RB. IL-17B induces an increased production of TNF-α and IL-1β in THP-1 cell line, and synergizes the effect of TNF-α on G-CSF and IL-6 expression by fibroblasts. IL-17B was shown to induce the migration of a B cell subset [55] and neutrophil in vivo [56]. IL-17B can oppose IL-17E-driven inflammation and has been shown to play an antagonistic role [57]. Several studies suggest that IL-17B plays important roles in embryonic organogenesis and tissue regeneration (reviewed in [58]).

In clinical and experimental breast cancers, IL-17B is found to be pro-tumoral. IL-17B and IL-17RB are associated with poor prognosis in patients and IL-17B expression upregulation is specifically associated with poorer survival [59,60]. Further, two separate studies revealed that IL-17B/IL-17RB upregulates anti-apoptotic proteins of the BCL-2 family, which induced resistance to etoposide and paclitaxel [59,60] (Figure 2).


IL-17C is secreted by epithelial cells in response to Toll-like receptor stimulation, which facilitates bacterial clearance through the recruitment of neutrophils [61]. Its expression has also been reported in T cells, dendritic cells and macrophages in inflamed tissues [62]. IL-17C acts via IL-17RA and IL-17RE and activates NF-κB, mediating a seemingly overlapping function to that of IL-17A and IL-17F. Its role in psoriasis is clear, but its implication in inflammation is beginning to be unraveled. IL-17C induces a similar pattern of gene expression to IL-17A, which poses the question of functional redundancy. IL- 17C is pro-tumoral in lung cancer [63]; its role in breast cancer is unknown.


IL-17D mRNA is detected in various tissues, including brain, heart, lung, pancreas, skeletal muscle and adipose tissue. In the immune system, expression seems to be restricted to naïve CD4+ T cells and B cells [64]. IL-17D most closely resembles IL-17B, with which it shares 27% homology. To date, its receptor remains unknown [57]. IL-17D has been shown to stimulate monocyte chemoattractant protein-1 (MCP-1) production from tumor endothelial cells, which leads to the recruitment of natural killer (NK) cells [65]. The action of IL-17D remains entirely obscure. Its expression in breast cancer is weak1, suggesting little impact on the disease progression.


IL-17E (IL-25) derives from both hematopoietic and non-hematopoietic cells and shares little homology with the other IL-17 members. IL-17E is expressed by innate immune cells such as mast cells and alveolar macrophages in response to allergic stimuli. Like IL-17B, IL-17E can bind to IL-17RA/IL-17RB, but with a higher affinity [66]. IL-17E is a pleiotropic cytokine, acting on stromal, innate immune and adaptive immune cells to orchestrate Th2- type inflammation [67], as mentioned above. Consistent with the association of dysregulated Th2 responses with the development of allergy, IL-17E production is linked to the severity of chronic allergic conditions. Thus, IL- 17E-induced inflammation can be distinguished from IL-17A- and IL-17F-induced inflammation through the nature of the immune infiltrate, which mostly consists of eosinophils for the former and neutrophils for the latter. However, IL-17E can inhibit Th17 development mainly by skewing the immune system toward a Th2 response, leading to the regulation of automimmune diseases [68] (Figure 2).

IL-17E receptor subunits IL-17RA/IL-17RB are upregulated in breast cancers versus normal samples. IL-17E, similarly to EGF, activates the epidermal growth factor receptor (EGFR) in triple-negative breast cancer (TNBC) cells that are resistant to EGFR inhibitors. It also activates the PYK-2, Src and STAT3 kinases, which are essential for EGFR activation and nuclear translocation [69]. Accordingly, IL-17A and IL-17E promoted resistance to docetaxel and failed to induce apoptosis, which contrasts with other studies demonstrating that IL-17E has anti-breast cancer activities [44,70-73].

Concluding Remarks

This review summarizes the literature regarding the impact of IL-17 members mainly in breast cancer development and resistance to therapies. From migration to modulation of cell phenotypes and function, IL-17 members exert a wide variety of biological effects on their target cells, which directly impact tumor growth. Taken alone, IL-17 members are discreet actors of inflammation.

However, when expressed within a myriad of other mediators, IL-17 members are able to synergize either pro- or anti-inflammatory processes. In particular, IL- 17A enhances both TLR- and inflammasome-dependent activities through synergic action on TNF-α [74] and IL- 1β [75] respectively. IL-17 members may then, as well, make a link between cancer and associated comorbidities such as obesity [76], high salt intake [77] and dysbiosis [75]. Treatment with anti-IL-17 holds a promise as cancer therapy. Several treatments targeting IL-17A have been approved and are in fact currently used successfully in some chronic inflammatory diseases with no significant adverse reactions despite the reported protector role of IL- 17A in infection [78] and in cardiovascular diseases [79]. These therapeutic agents, used alone or in combination with other cytokine inhibitors, could then potentially be employed as adjuvant treatment to overcome resistance to chemotherapy, checkpoint inhibitors and radiotherapy in breast cancer.

Author Contributions Statement

SP wrote the manuscript and designed the figures with support from JLC, RLN, AB, YM.